<?xml version="1.0" encoding="UTF-8"?>
<p>Vaccinia LAVs are potent but reactogenic, and complications are very uncommon but can be serious [
 <xref rid="B55-vaccines-08-00036" ref-type="bibr">55</xref>]. They are also unsuitable for immunocompromised individuals who would be most at risk in the case of an epidemic [
 <xref rid="B56-vaccines-08-00036" ref-type="bibr">56</xref>]. In light of recent outbreaks of known and novel zoonotic poxviruses [
 <xref rid="B57-vaccines-08-00036" ref-type="bibr">57</xref>,
 <xref rid="B58-vaccines-08-00036" ref-type="bibr">58</xref>,
 <xref rid="B59-vaccines-08-00036" ref-type="bibr">59</xref>,
 <xref rid="B60-vaccines-08-00036" ref-type="bibr">60</xref>] and the potential use of smallpox in bioterrorism [
 <xref rid="B51-vaccines-08-00036" ref-type="bibr">51</xref>], second-generation vaccines such as ACAM2000 [
 <xref rid="B61-vaccines-08-00036" ref-type="bibr">61</xref>] and CJ-50300 [
 <xref rid="B62-vaccines-08-00036" ref-type="bibr">62</xref>] have been derived from original vaccinia strains in tissue culture, and other LAVs have been made from the highly attenuated, modified vaccinia Ankara strain [
 <xref rid="B63-vaccines-08-00036" ref-type="bibr">63</xref>,
 <xref rid="B64-vaccines-08-00036" ref-type="bibr">64</xref>]. Further understanding of the interaction of vaccinia LAV with the human immune system will be a major part of developing new LAVs to combat 
 <italic>Orthpoxviruses</italic> in the future.
</p>
